Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. Stock
Heavy losses for Akebia Therapeutics Inc. today as the stock fell by -€0.059 (-4.550%).
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Akebia Therapeutics Inc..
With a target price of 4 € there is potential for a 222.84% increase which would mean more than doubling the current price of 1.24 € for Akebia Therapeutics Inc..
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | -4.550% | 3.336% | -5.420% | -24.405% | -7.121% | 121.250% | -51.220% |
| Heron Therapeutics Inc. | -3.340% | 12.739% | 1.659% | -50.864% | -28.501% | -67.883% | -94.618% |
| Evolus Inc | -0.540% | 7.961% | -10.945% | -55.318% | -29.083% | -48.467% | -57.056% |
| Sangamo Therapeutics Inc. | 0.250% | 1.388% | -29.790% | -61.259% | -33.162% | -84.467% | -97.559% |
Comments
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its price target lowered by BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat